Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation

Saved in:
Bibliographic Details
Published in中华医学杂志英文版 Vol. 136; no. 7; pp. 848 - 850
Main Authors Mao Shiqi, Luo Libo, Yang Shuo, Wang Yan, Zhou Fei, Yu Jia, Chen Bin, Gao Guanghui, Li Xuefei, Zhao Chao, Cheng Lei, Liu Yiwei, Wang Wanying, Jia Keyi, Shao Chuchu, Liu Xinyu, Chen Xiaoxia, Su Chunxia, Zhou Caicun, Wu Fengying, Ren Shengxiang
Format Journal Article
LanguageChinese
Published Department of Medical Oncology, Shanghai Pulmonary Hospital, Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China%Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China 2023
Online AccessGet full text
ISSN0366-6999
DOI10.1097/CM9.0000000000002453

Cover

More Information
ISSN:0366-6999
DOI:10.1097/CM9.0000000000002453